Fecha de recepción: 26/07/2017 – Fecha de aceptación: 19/12/2017
Marín-Gorricho R1, Alfaro-Olea A1, Casajus-Navasal A1, Serrano-Pérez A1, Nebot-Villacampa MJ2,
Zafra-Morales R2
1 Facultativo Especialista en Farmacia Hospitalaria
2 Residente de Farmacia Hospitalaria
Hospital San Pedro de Logroño. La Rioja (España)
____
Correspondencia:
Raquel Marín Gorricho
Hospital San Pedro de Logroño
(Servicio de Farmacia)
C/ Piqueras, 98
26006 Logroño (La Rioja)
Correo electrónico: raquelmg00@hotmail.com
____
SUMMARY
Objectives: To determine the incidence and severity of adverse events (AA) associated with first-line treatment with platinum doublets in patients with advanced non-small cell lung cancer in a third-level hospital. Describe and compare the toxicological profile of used platinum doublets.
Methods: Prospective observational study performed from January to July 2016. AAs of any grade were collected in each cycle of chemotherapy. They were evaluated according to NCI CTCAE version 4.03. Personal, anthropometric and clinical data were collected. A descriptive study of the most relevant variables was performed and the chi-square test or Fisher’s exact test was performed to assess the toxicological profile of both platinum (SPSS® version 21).
Results: 45 patients were started, 28 with cisplatin doublet and 17 with carboplatin. Twenty-six patients completed the treatment, the rest abandoned for different reasons. Almost all of them had some AA and 33.3% (15) suffered some serious illness. The number of AA collected was 196. Patients treated with cisplatin doublet had greater numbers of AA and greater gastrointestinal disturbances, neurotoxicity and asthenia. However, patients treated with carboplatin had greater thrombopenia and neutropenia.
Conclusions: The incidence and severity of the detected AAs are in accordance with the literature. The observed toxicity profile is different. Most AAs are of moderate severity and are treatable with supportive measures and drop at the end of treatment.
Key Words: Non-small cell lung carcinoma, carboplatin, cisplatin, toxicity, platinum compounds.
____
Descargar artículo en PDF: Toxicidad de los dobletes de platinos en el cáncer de pulmón no microcítico avanzado